DK1827441T3 - Kombinationer til behandling af sygdomme, som involverer celleproliferation - Google Patents

Kombinationer til behandling af sygdomme, som involverer celleproliferation

Info

Publication number: DK1827441T3
Authority: DK; Denmark
Prior art keywords: combinations; cell proliferation; treat diseases; involve cell; involve
Prior art date: 2004-08-14

Application number

DK05770228.4T

Other languages

English (en)

Inventor

Gerd Munzert

Martin Steegmaier

Anke Baum

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-14

Filing date

2005-08-09

Publication date

2011-07-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35241347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1827441(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-08-09 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2011-07-18 Application granted granted Critical

2011-07-18 Publication of DK1827441T3 publication Critical patent/DK1827441T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK05770228.4T 2004-08-14 2005-08-09 Kombinationer til behandling af sygdomme, som involverer celleproliferation DK1827441T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04019361		2004-08-14
EP04019448		2004-08-17
PCT/EP2005/008623 WO2006018182A1 (en)	2004-08-14	2005-08-09	Combinations for the treatment of diseases involving cell proliferation

Publications (1)

Publication Number	Publication Date
DK1827441T3 true DK1827441T3 (da)	2011-07-18

Family

ID=35241347

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK05770228.4T DK1827441T3 (da)	2004-08-14	2005-08-09	Kombinationer til behandling af sygdomme, som involverer celleproliferation
DK10184338.1T DK2275107T3 (da)	2004-08-14	2005-08-09	Kombinationer til behandling af sygdomme forbundet med celleproliferation.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK10184338.1T DK2275107T3 (da)	2004-08-14	2005-08-09	Kombinationer til behandling af sygdomme forbundet med celleproliferation.

Country Status (26)

Country	Link
US (3)	US20060058311A1 (da)
EP (2)	EP1827441B1 (da)
JP (1)	JP5043660B2 (da)
KR (1)	KR101258426B1 (da)
CN (1)	CN101039673B (da)
AR (1)	AR050521A1 (da)
AT (1)	ATE512663T1 (da)
AU (1)	AU2005274384B2 (da)
BR (1)	BRPI0514357A (da)
CA (1)	CA2576269C (da)
CY (1)	CY1112200T1 (da)
DK (2)	DK1827441T3 (da)
ES (1)	ES2602465T3 (da)
HR (1)	HRP20110578T1 (da)
HU (1)	HUE032436T2 (da)
IL (1)	IL181305A (da)
ME (1)	ME01209B (da)
MX (2)	MX2007001853A (da)
NZ (1)	NZ553729A (da)
PL (2)	PL1827441T3 (da)
PT (1)	PT1827441E (da)
RS (1)	RS51807B (da)
RU (2)	RU2407532C9 (da)
SI (1)	SI1827441T1 (da)
TW (2)	TWI361071B (da)
WO (1)	WO2006018182A1 (da)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA01012899A (es) *	1999-06-21	2002-07-30	Boehringer Ingelheim Pharma	Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
GB0011903D0 (en) *	2000-05-18	2000-07-05	Astrazeneca Ab	Combination chemotherapy
US7019012B2 (en) *	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de) *	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US6861422B2 (en) *	2003-02-26	2005-03-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) *	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
US20050096332A1 (en) *	2003-10-30	2005-05-05	Boehringer Ingelheim International Gmbh	Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
DE102004029784A1 (de) *	2004-06-21	2006-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) *	2004-07-09	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) *	2004-08-14	2006-02-16	Boehringer Ingelheim International Gmbh	Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) *	2004-08-14	2010-06-01	Boehringer Ingelheim International Gmbh	Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) *	2004-08-14	2010-07-20	Boehringer Ingelheim International Gmbh	Process for the manufacture of dihydropteridinones
US20060074088A1 (en) *	2004-08-14	2006-04-06	Boehringer Ingelheim International Gmbh	Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) *	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de)	2004-08-25	2006-03-01	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) *	2004-08-25	2006-03-08	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CZ296459B6 (cs) *	2004-09-14	2006-03-15	Pliva-Lachema A. S.	Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
DE102004058337A1 (de)	2004-12-02	2006-06-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
KR101313702B1 (ko)	2005-02-03	2013-10-04	와이어쓰	제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
AR057854A1 (es)	2005-11-04	2007-12-19	Wyeth Corp	Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
EP3173084B1 (en) *	2005-11-11	2019-10-23	Boehringer Ingelheim International GmbH	Quinazoline derivatives for the treatment of cancer diseases
PT1948180E (pt) *	2005-11-11	2013-05-10	Boehringer Ingelheim Int	Tratamento de combinação de cancro compreendendo inibidores de egfr/her2
US7960546B2 (en) *	2006-01-26	2011-06-14	Boehringer Ingelheim International Gmbh	Process for preparing aminocrotonylamino-substituted quinazoline derivatives
US7439358B2 (en) *	2006-02-08	2008-10-21	Boehringer Ingelheim International Gmbh	Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2007139939A2 (en) *	2006-05-26	2007-12-06	Celgene Corporation	Methods and compositions using immunomodulatory compounds in combination therapy
TW200808325A (en) *	2006-07-06	2008-02-16	Astrazeneca Ab	Novel compounds
ES2385613T3 (es) *	2006-09-18	2012-07-27	Boehringer Ingelheim International Gmbh	Método para tratar cánceres que portan mutaciones de EGFR
NZ576278A (en) *	2006-10-19	2011-12-22	Signal Pharm Llc	Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
US8168661B2 (en) *	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8178564B2 (en) *	2006-11-06	2012-05-15	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8173686B2 (en)	2006-11-06	2012-05-08	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
US8168662B1 (en)	2006-11-06	2012-05-01	Poniard Pharmaceuticals, Inc.	Use of picoplatin to treat colorectal cancer
NZ577638A (en)	2006-12-14	2012-03-30	Vertex Pharma	Tricyclic fused compounds useful as protein kinase inhibitors
US20110033528A1 (en) *	2009-08-05	2011-02-10	Poniard Pharmaceuticals, Inc.	Stabilized picoplatin oral dosage form
TW200916094A (en) *	2007-06-27	2009-04-16	Poniard Pharmaceuticals Inc	Stabilized picoplatin dosage form
US20100260832A1 (en) *	2007-06-27	2010-10-14	Poniard Pharmaceuticals, Inc.	Combination therapy for ovarian cancer
JP2010533714A (ja) *	2007-07-16	2010-10-28	ポニアードファーマシューティカルズ，インコーポレイテッド	ピコプラチンのための経口製剤
EP2185559A1 (en) *	2007-08-03	2010-05-19	Boehringer Ingelheim International GmbH	Crystalline form of a dihydropteridione derivative
US8754094B2 (en) *	2007-08-15	2014-06-17	The Research Foundation Of State University Of New York	Methods for heat shock protein dependent cancer treatment
AU2016225895B2 (en) *	2007-10-17	2018-02-08	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-)dimethylamino)-2-butenamide and crystalline forms thereof
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101998851A (zh) *	2008-02-08	2011-03-30	帕纳德制药公司	吡铂和西妥昔单抗治疗结直肠癌的用途
EP2100894A1 (en)	2008-03-12	2009-09-16	4Sc Ag	Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
KR101725469B1 (ko) *	2008-06-06	2017-04-11	베링거 인겔하임 인터내셔날 게엠베하	인돌리논 유도체의 현탁 제형을 포함하는 캡슐 약제학적 투여 형태
AU2015227503B2 (en) *	2008-06-06	2017-02-23	Boehringer Ingelheim International Gmbh	Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
US20170065529A1 (en)	2015-09-09	2017-03-09	Boehringer Ingelheim International Gmbh	Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) *	2008-06-06	2015-01-26		Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
PE20100252A1 (es) *	2008-06-06	2010-04-12	Boehringer Ingelheim Int	Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
EA020046B1 (ru) *	2008-06-06	2014-08-29	Бёрингер Ингельхайм Интернациональ Гмбх	Фармацевтическая комбинация
NZ616613A (en)	2008-06-17	2015-05-29	Wyeth Llc	Antineoplastic combinations containing hki-272 and vinorelbine
NZ590266A (en) *	2008-06-23	2012-08-31	Vertex Pharma	Protein kinase inhibitors based on dihydro-5h-pyrimido[4,5-b]diazepin or dihydropteridin
KR20140069340A (ko)	2008-08-04	2014-06-09	와이어쓰 엘엘씨	4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
WO2010059589A1 (en) *	2008-11-21	2010-05-27	Isis Pharmaceuticals, Inc.	Anticancer combination comprising docetaxel and an antisense oligonucleotide
WO2010064422A1 (ja) *	2008-12-02	2010-06-10	静岡県公立大学法人	ヒストン高アセチル化状態における光増感処理による腫瘍殺傷法
NZ595143A (en)	2009-04-06	2014-01-31	Wyeth Llc	Treatment regimen utilizing neratinib for breast cancer
KR101224468B1 (ko) *	2009-05-20	2013-01-23	주식회사 파멥신	신규한 형태의 이중표적항체 및 그 용도
ES2731901T3 (es)	2009-07-06	2019-11-19	Boehringer Ingelheim Int	Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
WO2011019630A2 (en)	2009-08-10	2011-02-17	Board Of Regents, The University Of Texas System	Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors
JO3002B1 (ar)	2009-08-28	2016-09-05	Irm Llc	مركبات و تركيبات كمثبطات كيناز بروتين
CN102020643A (zh)	2009-09-22	2011-04-20	上海恒瑞医药有限公司	二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
WO2011049625A1 (en)	2009-10-20	2011-04-28	Mansour Samadpour	Method for aflatoxin screening of products
EP2496567B1 (en)	2009-11-05	2017-07-12	Rhizen Pharmaceuticals S.A.	Novel benzopyran kinase modulators
EP2992878A1 (en)	2010-02-03	2016-03-09	Signal Pharmaceuticals, LLC	Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
EP2536725B1 (en) *	2010-02-17	2015-10-28	Boehringer Ingelheim International GmbH	Dihydropteridinones, method for production and use thereof
WO2011143669A2 (en)	2010-05-14	2011-11-17	Dana-Farber Cancer Institute, Inc	Compositions and methods for treating neoplasia, inflammatory disease and other disorders
CN103180318B (zh)	2010-05-14	2017-05-10	达那-法伯癌症研究所	雄性避孕组合物以及使用方法
CN102985111B (zh) *	2010-05-14	2014-05-07	香港大学	Gep抗体及其用途
EP2569434B1 (en)	2010-05-14	2019-09-04	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating leukemia and related disorders
SG186885A1 (en)	2010-06-04	2013-02-28	Albany Molecular Res Inc	Glycine transporter-1 inhibitors, methods of making them, and uses thereof
PL2608792T3 (pl)	2010-08-26	2018-03-30	Boehringer Ingelheim International Gmbh	Sposoby podawania inhibitora EGFR
US8546566B2 (en)	2010-10-12	2013-10-01	Boehringer Ingelheim International Gmbh	Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en)	2010-11-29	2016-06-07	Boehringer Ingelheim International Gmbh	Method for treating acute myeloid leukemia
WO2012079075A1 (en)	2010-12-10	2012-06-14	Concert Pharmaceuticals, Inc.	Deuterated phthalimide derivatives
WO2012148548A1 (en)	2011-02-25	2012-11-01	Takeda Pharmaceutical Company Limited	N-substituted oxazinopteridines and oxazinopteridinones
JP6118314B2 (ja)	2011-05-04	2017-04-19	ライゼン・ファーマシューティカルズ・エスアー	タンパク質キナーゼのモジュレーターとしての新規化合物
US20130131069A1 (en) *	2011-05-13	2013-05-23	Boehringer Ingelheim International Gmbh	Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US8828391B2 (en)	2011-05-17	2014-09-09	Boehringer Ingelheim International Gmbh	Method for EGFR directed combination treatment of non-small cell lung cancer
US9370535B2 (en)	2011-05-17	2016-06-21	Boehringer Ingelheim International Gmbh	Method for treatment of advanced solid tumors
WO2013130849A1 (en)	2012-02-29	2013-09-06	Concert Pharmaceuticals, Inc.	Substituted dioxopiperidinyl phthalimide derivatives
US9249093B2 (en)	2012-04-20	2016-02-02	Concert Pharmaceuticals, Inc.	Deuterated rigosertib
CN104470923B (zh)	2012-07-04	2019-03-29	理森制药股份公司	选择性PI3K δ抑制剂
EP2875020B1 (en)	2012-07-19	2017-09-06	Boehringer Ingelheim International GmbH	Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
CN104780976B (zh)	2012-08-13	2019-01-01	洛克菲勒大学	治疗和诊断黑素瘤
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9643950B2 (en)	2012-10-22	2017-05-09	Concert Pharmaceuticals, Inc.	Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
WO2014110322A2 (en)	2013-01-11	2014-07-17	Concert Pharmaceuticals, Inc.	Substituted dioxopiperidinyl phthalimide derivatives
US9714946B2 (en)	2013-03-14	2017-07-25	Dana-Farber Cancer Institute, Inc.	Bromodomain binding reagents and uses thereof
MX364101B (es)	2013-04-17	2019-04-12	Signal Pharm Llc	Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
WO2014172426A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Treatment of cancer with dihydropyrazino-pyrazines
US9359364B2 (en)	2013-04-17	2016-06-07	Signal Pharmaceuticals, Llc	Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one
US9782427B2 (en)	2013-04-17	2017-10-10	Signal Pharmaceuticals, Llc	Methods for treating cancer using TOR kinase inhibitor combination therapy
MX368286B (es)	2013-04-17	2019-09-27	Signal Pharm Llc	Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
MX2015014455A (es)	2013-04-17	2016-07-21	Signal Pharm Llc	Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
UA119538C2 (uk)	2013-04-17	2019-07-10	Сігнал Фармасьютікалз, Елелсі	Лікування злоякісної пухлини дигідропіразинопіразинами
CA2912627C (en)	2013-05-29	2022-03-15	Signal Pharmaceuticals, Llc	Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
KR20160034379A (ko)	2013-07-25	2016-03-29	다나-파버 캔서 인스티튜트 인크.	전사 인자의 억제제 및 그의 용도
MX2016001087A (es) *	2013-07-26	2016-04-20	Boehringer Ingelheim Int	Volasertib en combinacion con azacitidina para el tratamiento de leucemia mieloide aguda y sindrome mielodisplasico.
EP3024464A1 (en)	2013-07-26	2016-06-01	Boehringer Ingelheim International GmbH	Treatment of myelodysplastic syndrome
CA2919294A1 (en) *	2013-07-26	2015-01-29	Boehringer Ingelheim International Gmbh	Volasertib in combination with decitabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii
MX2016005980A (es)	2013-11-08	2016-12-09	Dana Farber Cancer Inst Inc	Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015106012A1 (en)	2014-01-09	2015-07-16	Takeda Pharmaceutical Company Limited	Azaindole derivatives
US10793571B2 (en)	2014-01-31	2020-10-06	Dana-Farber Cancer Institute, Inc.	Uses of diazepane derivatives
JP2017504650A (ja)	2014-01-31	2017-02-09	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	ジアゼパン誘導体およびその使用
CN106029653A (zh)	2014-01-31	2016-10-12	达纳-法伯癌症研究所股份有限公司	二氨基嘧啶苯砜衍生物及其用途
MX2016009975A (es) *	2014-01-31	2016-10-31	Dana Farber Cancer Inst Inc	Derivados de dihidropteridinona y sus usos.
MX2016011160A (es)	2014-02-28	2017-04-27	Tensha Therapeutics Inc	Tratamiento de afecciones asociadas con la hiperinsulinemia.
WO2015160880A1 (en)	2014-04-16	2015-10-22	Signal Pharmaceuticals, Llc	SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3177626A4 (en)	2014-08-08	2017-12-27	Dana Farber Cancer Institute, Inc.	Diazepane derivatives and uses thereof
WO2016022970A1 (en)	2014-08-08	2016-02-11	Dana-Farber Cancer Institute, Inc.	Dihydropteridinone derivatives and uses thereof
US9867831B2 (en)	2014-10-01	2018-01-16	Boehringer Ingelheim International Gmbh	Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
SG11201703414VA (en)	2014-10-27	2017-05-30	Tensha Therapeutics Inc	Bromodomain inhibitors
CN105566290B (zh)	2014-10-30	2020-05-22	康朴生物医药技术（上海）有限公司	异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用
CN106279173A (zh) *	2015-05-29	2017-01-04	华东理工大学	蝶啶酮衍生物作为egfr抑制剂的应用
WO2016201370A1 (en)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
SG10202007090UA (en)	2015-09-11	2020-08-28	Dana Farber Cancer Inst Inc	Cyano thienotriazolodiazepines and uses thereof
UA123946C2 (uk)	2015-09-11	2021-06-30	Дана-Фарбер Кенсер Інстітьют, Інк.	Ацетамідтієнотриазолодіазепіни й шляхи їх застосування
JP7385356B2 (ja)	2015-11-25	2023-11-22	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	二価ブロモドメインインヒビターおよびそれらの使用
DE102017005091A1 (de)	2016-05-30	2017-11-30	Bayer Pharma Aktiengesellschaft	Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
DE102017005089A1 (de)	2016-05-30	2017-11-30	Bayer Pharma Aktiengesellschaft	Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
CN106831765B (zh) *	2016-12-28	2018-12-14	郑州大学	2-(2,6-二氰基苯基)咪唑并[1,2-α]吡啶类化合物及其制备方法
AU2018228541B2 (en)	2017-02-28	2020-07-16	Kangpu Biopharmaceuticals, Ltd.	Novel isoindoline derivative, and pharmaceutical composition and application thereof
PL3624786T3 (pl)	2017-05-16	2023-10-30	Ability Pharmaceuticals S.A.	Kombinacja farmaceutyczna do leczenia nowotworu
WO2018237114A1 (en)	2017-06-22	2018-12-27	Celgene Corporation	TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION
CN109776788B (zh) *	2017-11-14	2021-07-30	博瑞生物医药（苏州）股份有限公司	叶酸受体靶向多臂偶联物
WO2019145410A1 (en)	2018-01-25	2019-08-01	Boehringer Ingelheim International Gmbh	Combination treatment of acute myeloid leukemia
CA3097774A1 (en) *	2018-04-24	2019-10-31	Vertex Pharmaceuticals Incorporated	Pteridinone compounds and uses thereof
CN111285850B (zh)	2018-12-06	2022-04-22	中国科学院上海药物研究所	一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
JOP20210298A1 (ar)	2019-05-14	2023-01-30	Provention Bio Inc	طرق وتركيبات للوقاية من مرض السكري من النوع الأول
CN110156700A (zh) *	2019-06-05	2019-08-23	鲁南制药集团股份有限公司	吉非替尼与水杨酸共晶体
CA3161274A1 (en)	2019-12-13	2021-06-17	Stephen Wald	Metal salts and uses thereof
CA3182445A1 (en)	2020-06-11	2021-12-16	Francisco Leon	Methods and compositions for preventing type 1 diabetes

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8303657A (nl)	1983-10-24	1985-05-17	Pharmachemie Bv	Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan.
DE3537761A1 (de)	1985-10-24	1987-04-30	Bayer Ag	Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
JPH0276860A (ja)	1987-10-05	1990-03-16	Toyo Jozo Co Ltd	６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体
DE68908786T2 (de)	1988-06-16	1994-03-17	Smith Kline French Lab	Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
FR2645152B1 (fr)	1989-03-30	1991-05-31	Lipha	3h-pteridinones-4, procedes de preparation et medicaments les contenant
US5043270A (en) *	1989-03-31	1991-08-27	The Board Of Trustees Of The Leland Stanford Junior University	Intronic overexpression vectors
CA2029651C (en)	1989-11-17	2000-06-06	David D. Davey	Tricyclic pteridinones and a process for their preparation
US5198547A (en)	1992-03-16	1993-03-30	South Alabama Medical Science Foundation, Usa	Process for N5-formylating tetrahydropteridines
TW274550B (da)	1992-09-26	1996-04-21	Hoechst Ag
EP1195372A1 (en)	1994-04-18	2002-04-10	Mitsubishi Pharma Corporation	N-heterocyclic substituted benzamide derivatives with antihypertensive activity
GB9418499D0 (en)	1994-09-14	1994-11-02	Ciba Geigy Ag	Process for producing n-methylated organic pigments
CO4410191A1 (es)	1994-09-19	1997-01-09	Lilly Co Eli	SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
IL117923A (en)	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
EP0825979B1 (en)	1995-05-19	2001-01-03	Novartis AG	Process for the catalytic hydrogenation of aromatic nitro compounds
US5698556A (en)	1995-06-07	1997-12-16	Chan; Carcy L.	Methotrexate analogs and methods of using same
AU720366B2 (en)	1996-09-23	2000-06-01	Eli Lilly And Company	Olanzapine dihydrate D
EP1104420B1 (en)	1998-08-11	2002-12-18	Pfizer Products Inc.	Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors
WO2000043369A1 (en)	1999-01-22	2000-07-27	Elan Pharmaceuticals, Inc.	Compounds which inhibit leukocyte adhesion mediated by vla-4
CN1373763A (zh)	1999-09-15	2002-10-09	沃尼尔·朗伯公司	作为激酶抑制剂的蝶啶酮
UA75054C2 (uk) *	1999-10-13	2006-03-15	Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг	Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
GB2359551A (en)	2000-02-23	2001-08-29	Astrazeneca Uk Ltd	Pharmaceutically active pyrimidine derivatives
AU2001233028A1 (en)	2000-03-06	2001-10-03	Warner-Lambert Company	5-alkylpyrido(2,3-D)pyrimidines tyrosine kinase inhibitors
DE10018783A1 (de)	2000-04-15	2001-10-25	Fresenius Kabi De Gmbh	Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
US20020183292A1 (en)	2000-10-31	2002-12-05	Michel Pairet	Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10058119A1 (de)	2000-11-22	2002-05-23	Bayer Ag	Pepinotan-Kit
ES2236481T3 (es) *	2001-01-16	2005-07-16	Glaxo Group Limited	Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
US6756374B2 (en)	2001-01-22	2004-06-29	Hoffmann-La Roche Inc.	Diaminothiazoles having antiproliferative activity
WO2002076954A1 (en)	2001-03-23	2002-10-03	Smithkline Beecham Corporation	Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076985A1 (en)	2001-03-23	2002-10-03	Smithkline Beecham Corporation	Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030055026A1 (en)	2001-04-17	2003-03-20	Dey L.P.	Formoterol/steroid bronchodilating compositions and methods of use thereof
EA007062B1 (ru)	2001-09-04	2006-06-30	Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг	Новые дигидроптеридиноны, способы их получения и их применение в качестве лекарственных средств
US6806272B2 (en) *	2001-09-04	2004-10-19	Boehringer Ingelheim Pharma Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
BRPI0117198B1 (pt)	2001-12-14	2018-03-13	Merck Serono S.A.	Usos de composição compreendendo um inibidor seletivo de uma isoforma 4 de fosfodiesterase
US20060079503A1 (en)	2002-05-03	2006-04-13	Schering Aktiengesellschaft	Thiazolidinones and the use therof as polo-like kinase inhibitors
PE20040701A1 (es) *	2002-07-23	2004-11-30	Boehringer Ingelheim Pharma	Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos
FR2843114B1 (fr)	2002-08-01	2004-09-10	Poudres & Explosifs Ste Nale	Procede de monomethylation d'heterocycles azotes
BR0313160A (pt)	2002-08-08	2005-07-12	Smithkline Beecham Corp	Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
US6861422B2 (en) *	2003-02-26	2005-03-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
RS52386B (en)	2003-02-26	2013-02-28	Boehringer Ingelheim Pharma Gmbh & Co.Kg.	DIHYDROPTERIDINONE, PROCEDURE FOR THEIR PREPARATION AND THEIR APPLICATION AS A MEDICINE
DK1605971T3 (da)	2003-03-26	2010-08-16	Wyeth Llc	Immunogene sammensætninger og fremgangsmåder
EP1617820B1 (en)	2003-04-14	2018-03-21	Vectura Limited	Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
WO2005067935A1 (de)	2004-01-17	2005-07-28	Boehringer Ingelheim International Gmbh	Verwendung von substituierten pteridinen zur behandlung von atemwegserkrankungen
DE102004002557A1 (de)	2004-01-17	2005-08-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de)	2004-06-21	2006-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de)	2004-07-09	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
DE102004034623A1 (de)	2004-07-16	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060035903A1 (en)	2004-08-14	2006-02-16	Boehringer Ingelheim International Gmbh	Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en)	2004-08-14	2010-07-20	Boehringer Ingelheim International Gmbh	Process for the manufacture of dihydropteridinones
US7728134B2 (en)	2004-08-14	2010-06-01	Boehringer Ingelheim International Gmbh	Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en)	2004-08-14	2006-04-06	Boehringer Ingelheim International Gmbh	Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
EP1632493A1 (de)	2004-08-25	2006-03-08	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de)	2004-08-25	2006-03-01	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en)	2004-08-26	2006-03-02	Boehringer Ingelheim International Gmbh	Pteridinones used as plk (polo like kinase) inhibitors
WO2006021548A1 (de)	2004-08-27	2006-03-02	Boehringer Ingelheim International Gmbh	Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE102004058337A1 (de)	2004-12-02	2006-06-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
CA2617589A1 (en)	2005-08-03	2007-02-08	Boehringer Ingelheim International Gmbh	Dihydropteridinones in the treatment of respiratory diseases
PT1948180E (pt)	2005-11-11	2013-05-10	Boehringer Ingelheim Int	Tratamento de combinação de cancro compreendendo inibidores de egfr/her2
US7439358B2 (en)	2006-02-08	2008-10-21	Boehringer Ingelheim International Gmbh	Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP1994002A1 (en)	2006-03-07	2008-11-26	AstraZeneca AB	Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them
CA2873524C (en)	2006-05-04	2018-02-20	Boehringer Ingelheim International Gmbh	A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
EP2185559A1 (en)	2007-08-03	2010-05-19	Boehringer Ingelheim International GmbH	Crystalline form of a dihydropteridione derivative
JP4642085B2 (ja)	2008-01-17	2011-03-02	日本下水道事業団	予測健全度を利用した施設管理および更新計画システム
EP2100894A1 (en)	2008-03-12	2009-09-16	4Sc Ag	Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2536725B1 (en)	2010-02-17	2015-10-28	Boehringer Ingelheim International GmbH	Dihydropteridinones, method for production and use thereof
US8546566B2 (en)	2010-10-12	2013-10-01	Boehringer Ingelheim International Gmbh	Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en)	2010-11-29	2016-06-07	Boehringer Ingelheim International Gmbh	Method for treating acute myeloid leukemia
US20130131069A1 (en)	2011-05-13	2013-05-23	Boehringer Ingelheim International Gmbh	Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US9370535B2 (en)	2011-05-17	2016-06-21	Boehringer Ingelheim International Gmbh	Method for treatment of advanced solid tumors

2005
- 2005-07-26 US US11/189,540 patent/US20060058311A1/en not_active Abandoned
- 2005-08-09 BR BRPI0514357-8A patent/BRPI0514357A/pt active Search and Examination
- 2005-08-09 CN CN2005800352724A patent/CN101039673B/zh not_active Expired - Fee Related
- 2005-08-09 ES ES10184338.1T patent/ES2602465T3/es active Active
- 2005-08-09 DK DK05770228.4T patent/DK1827441T3/da active
- 2005-08-09 KR KR1020077005955A patent/KR101258426B1/ko not_active IP Right Cessation
- 2005-08-09 AT AT05770228T patent/ATE512663T1/de active
- 2005-08-09 PL PL05770228T patent/PL1827441T3/pl unknown
- 2005-08-09 RU RU2007109108/15A patent/RU2407532C9/ru not_active IP Right Cessation
- 2005-08-09 HU HUE10184338A patent/HUE032436T2/en unknown
- 2005-08-09 PT PT05770228T patent/PT1827441E/pt unknown
- 2005-08-09 EP EP05770228A patent/EP1827441B1/en active Active
- 2005-08-09 DK DK10184338.1T patent/DK2275107T3/da active
- 2005-08-09 WO PCT/EP2005/008623 patent/WO2006018182A1/en active Application Filing
- 2005-08-09 ME MEP-2011-124A patent/ME01209B/me unknown
- 2005-08-09 AU AU2005274384A patent/AU2005274384B2/en not_active Ceased
- 2005-08-09 MX MX2007001853A patent/MX2007001853A/es active IP Right Grant
- 2005-08-09 RS RS20110302A patent/RS51807B/en unknown
- 2005-08-09 SI SI200531347T patent/SI1827441T1/sl unknown
- 2005-08-09 EP EP10184338.1A patent/EP2275107B1/en active Active
- 2005-08-09 NZ NZ553729A patent/NZ553729A/en not_active IP Right Cessation
- 2005-08-09 CA CA2576269A patent/CA2576269C/en not_active Expired - Fee Related
- 2005-08-09 PL PL10184338T patent/PL2275107T3/pl unknown
- 2005-08-09 JP JP2007526349A patent/JP5043660B2/ja active Active
- 2005-08-12 TW TW094127595A patent/TWI361071B/zh active
- 2005-08-12 TW TW100137048A patent/TW201201810A/zh unknown
- 2005-08-12 AR ARP050103380A patent/AR050521A1/es unknown
2007
- 2007-02-13 IL IL181305A patent/IL181305A/en not_active IP Right Cessation
- 2007-02-14 MX MX2012003352A patent/MX340965B/es unknown
2009
- 2009-05-07 US US12/437,280 patent/US8143247B2/en active Active
2010
- 2010-09-01 RU RU2010136326/15A patent/RU2521394C2/ru not_active IP Right Cessation
2011
- 2011-08-03 HR HR20110578T patent/HRP20110578T1/hr unknown
- 2011-09-13 CY CY20111100877T patent/CY1112200T1/el unknown
2012
- 2012-01-03 US US13/342,507 patent/US8591895B2/en active Active

Also Published As

Publication number	Publication date
US20060058311A1 (en)	2006-03-16
ES2602465T3 (es)	2017-02-21
KR101258426B1 (ko)	2013-04-30
RU2407532C9 (ru)	2011-12-20
DK2275107T3 (da)	2017-01-09
PL2275107T3 (pl)	2017-05-31
AR050521A1 (es)	2006-11-01
TW200614992A (en)	2006-05-16
AU2005274384A1 (en)	2006-02-23
US20120107312A1 (en)	2012-05-03
ME01209B (me)	2013-06-20
US20090238828A1 (en)	2009-09-24
EP1827441B1 (en)	2011-06-15
CY1112200T1 (el)	2015-12-09
TW201201810A (en)	2012-01-16
MX2007001853A (es)	2007-03-28
SI1827441T1 (sl)	2011-09-30
HRP20110578T1 (hr)	2011-09-30
IL181305A (en)	2013-12-31
RU2010136326A (ru)	2012-03-10
HUE032436T2 (en)	2017-09-28
MX340965B (es)	2016-08-02
EP1827441A1 (en)	2007-09-05
CN101039673A (zh)	2007-09-19
US8143247B2 (en)	2012-03-27
EP2275107A2 (en)	2011-01-19
EP2275107B1 (en)	2016-10-05
RU2521394C2 (ru)	2014-06-27
BRPI0514357A (pt)	2008-06-10
AU2005274384B2 (en)	2011-06-23
RU2007109108A (ru)	2008-09-20
TWI361071B (en)	2012-04-01
NZ553729A (en)	2011-01-28
EP2275107A3 (en)	2013-06-26
IL181305A0 (en)	2007-07-04
JP5043660B2 (ja)	2012-10-10
CA2576269A1 (en)	2006-02-23
CA2576269C (en)	2014-01-28
KR20070050478A (ko)	2007-05-15
RU2407532C2 (ru)	2010-12-27
CN101039673B (zh)	2013-10-16
ATE512663T1 (de)	2011-07-15
US8591895B2 (en)	2013-11-26
WO2006018182A1 (en)	2006-02-23
JP2008509948A (ja)	2008-04-03
PT1827441E (pt)	2011-07-14
PL1827441T3 (pl)	2011-11-30
RS51807B (en)	2011-12-31
WO2006018182A8 (en)	2006-06-08

Publication	Publication Date	Title
DK1827441T3 (da)	2011-07-18	Kombinationer til behandling af sygdomme, som involverer celleproliferation
DE602005022897D1 (de)	2010-09-23	Piperidinylamino-thienoä2,3-dü-pyrimidinverbindungen
BRPI0508788A (pt)	2007-09-04	tiadiazolidinonas como inibidores de sqg - 3
ATE513831T1 (de)	2011-07-15	Pyridinä3,4-büpyrazinone
NL1028967A1 (nl)	2005-11-08	4-Fenylamino-chinazoline-6-yl-amiden.
IS8570A (is)	2006-11-20	Stoðfrumulaus framhaldsrækt stofnfrumna
DE602004027424D1 (de)	2010-07-08	Operationsverwaltungsprogramm, operationsverwaltun
DK1748781T3 (da)	2013-02-11	Fremgangsmåder til behandling af blødningsforstyrrelser under anvendelse af sulfaterede polysaccharider
DK2041069T3 (da)	2012-02-27	Benzylaminer, fremgangsmåde til fremstilling deraf og deres anvendelse som anti-inflammatoriske midler
DE602004011999D1 (de)	2008-04-03	Mehrbenutzer-übertragungssystem
NL1034762A1 (nl)	2008-06-06	Lichtdiffusieplaat.
FI20055644A0 (fi)	2005-12-02	Ryhmäviestintä
DE602005013516D1 (de)	2009-05-07	Nockenrolle
BRPI0511774A (pt)	2007-12-18	método para tratar biossólidos
NO20040762D0 (no)	2004-02-20	Stromskinne.
FIU20060462U0 (fi)	2006-11-06	Pehmuste
AT503057A3 (de)	2007-12-15	Entrindungsmechanismus
EP1784926A4 (en)	2009-07-22	INTERCONNECTED NANOSYSTEMS
NL1035334A1 (nl)	2008-10-30	Lichtdiffusieplaat.
ES1058102Y (es)	2005-02-16	Lentilla terapeutica.
DK1720557T3 (da)	2011-02-14	Hurtig-opløselig, smagsmaskeret tablet
AT503056A3 (de)	2007-12-15	Entrindungsmechanismus
FR2876232B3 (fr)	2006-08-11	Convertisseur-thermo-electrique solaire
NL1028622A1 (nl)	2005-09-27	Stelwig.
FI20041628A0 (fi)	2004-12-20	Kolmiulotteinen, optinen mittausjärjestelmä